A Systematic Review and Meta-Analysis of Metabolic Syndrome
                    Prevalence in Chinese Inpatients with Bipolar Disorder

Tao, Hejian; Dong, Shen; Zhou, Yong; Sun, Fei; Li, Guorong; Jin, Weidong

doi:10.1055/a-1882-8423

Cited by 4 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent meta-analysis reported an obesity prevalence of 29.0% among BD patients, with 22.4% having impaired fasting glucose (>100 mg/dL) [18]. In a study of hospitalized Chinese patients, BD was associated with MetS in 33% of cases [19]. Generally, our study's findings align with these prior studies, although the hyperglycemia prevalence was slightly elevated.…”

Section: Discussionsupporting

confidence: 88%

Effect of Metabolic Syndrome and Metabolic Abnormalities on Remission of Bipolar Disorder Inpatients: A Retrospective Chart Review Study

Kim,

Woo,

Choi

et al. 2024

Mood Emot

View full text Add to dashboard Cite

Background: Associations between metabolic abnormalities and poor treatment outcomes in bipolar disorder (BD) have been reported. This study examined the influence of metabolic abnormalities on remission in Korean inpatients with BD. Methods: This study retrospectively reviewed the chart of 128 adult patients with BD who were hospitalized at a university hospital in Korea. The collected data included fasting plasma glucose, total cholesterol, triglycerides, and high-density lipoprotein levels at admission, as well as height, weight, and blood pressure measurements. The prevalence of metabolic abnormalities was compared between the remission (17-item Hamilton Depression Rating Scale score of ≤7 and Young Mania Rating Scale score of <8) and nonremission groups. Results: Prevalence of hyperglycemia and hypertriglyceridemia significantly differed between the nonremission and remission groups. Multivariate analysis revealed hyperglycemia as the only significant risk factor for nonremission in subjects with mood and manic/hypomanic episodes. Conclusion:The study findings reveal a negative effect of hyperglycemia on the treatment outcome of BD. Clinical attention to metabolic abnormalities, specifically insulin resistance and hyperglycemia, is recommended during early stages of the disease.

show abstract

Section: Discussionsupporting

confidence: 88%

Effect of Metabolic Syndrome and Metabolic Abnormalities on Remission of Bipolar Disorder Inpatients: A Retrospective Chart Review Study

Kim,

Woo,

Choi

et al. 2024

Mood Emot

View full text Add to dashboard Cite

show abstract

Prevalence of metabolic syndrome and its components according to altitude levels: a systematic review and meta-analysis

Zila-Velasque,

Grados-Espinoza,

Challapa-Mamani

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Metabolic syndrome has a multifactorial origin; however, epidemiological data correspond to populations located at sea level. It has been reported that the altitude can affected the prevalence due to physiological changes. The aim of this study is to show the global prevalence of metabolic syndrome at altitude and its components. We use four databases, all studies published up to November 2023. The prevalences from studies were meta-analyzed using a random-effects model. To assess sources of heterogeneity, subgroup analyses were performed. We included 28 studies. The number of participants was 29 195. The prevalence of metabolic syndrome was 30.3% (95% CI 22.8–38.4%). According to the altitude level, at 1500–2500 was 36.5%, 2500–3500 (21.8%), and > 3500 (30.9%), also it was higher in women (35.5%) that men (26.8%). It was observed that there is an inverse relationship between higher altitude and the prevalence of metabolic syndrome. Among its components, abdominal obesity and low HDL were present in more than 40.0%, while high blood pressure, high triglycerides and impaired glucose were present in less than 30.0%. We recommend that our results be considered for future research in populations living at altitude since they have different characteristics from populations at sea level.

show abstract

Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial

Xie,

Shao,

Long

et al. 2024

Lipids Health Dis

View full text Add to dashboard Cite

Background Weight gain and metabolic disorders are commonly induced by antipsychotics. Orlistat is a lipase inhibitor used for weight control. The effect of orlistat on weight gain and metabolic disturbances in people (especially women) treated with antipsychotics has not been sufficiently studied. This study aimed to investigate the efficacy of orlistat in mitigating antipsychotic-induced weight gain and abnormal glycolipid metabolism. Methods Patients with schizophrenia or bipolar disorder with a weight gain ≥ 7% after taking antipsychotics were recruited. Participants were randomly allocated to two groups: one received eight weeks of orlistat (360 mg/day) and the other received a placebo. Anthropometric and fasting serum biochemical parameters were measured at baseline, week 4 and week 8. Results Sixty individuals (orlistat:placebo = 32:28) participated in the study. After controlling for the study center, the eight-week changes in body mass index (BMI), cholesterol (CHOL), high-density lipoprotein cholesterol (HDL-CH) and low-density lipoprotein cholesterol (LDL-CH) were significantly different between the groups. According to the mixed linear models, CHOL and LDL-CH were significantly lower in the orlistat group than in the control group at week 8. The week 0-to-8 slopes of BMI, CHOL and LDL-CH were also significantly lower in the orlistat group. Conclusions These findings suggested that orlistat is an effective intervention for attenuating weight gain and serum lipid disturbances in antipsychotic-treated patients. Trial registration ClinicalTrials.gov NCT03451734.

show abstract

A Systematic Review and Meta-Analysis of Metabolic Syndrome Prevalence in Chinese Inpatients with Bipolar Disorder

Cited by 4 publications

References 24 publications

Effect of Metabolic Syndrome and Metabolic Abnormalities on Remission of Bipolar Disorder Inpatients: A Retrospective Chart Review Study

Effect of Metabolic Syndrome and Metabolic Abnormalities on Remission of Bipolar Disorder Inpatients: A Retrospective Chart Review Study

Prevalence of metabolic syndrome and its components according to altitude levels: a systematic review and meta-analysis

Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial

Contact Info

Product

Resources

About